Sharps Technology signs for $75 million debt financing to buy InjectEZ

By Wendy Van Sickle

Columbus, Ohio, Sept. 28 – Sharps Technology, Inc. said it has signed term sheet with a middle-market lender for up to $75 million of debt financing for use in its acquisition of InjectEZ, a specialty prefillable syringe manufacturing facility, according to a news release.

The middle-market lender was not named in the release.

Proceeds from the financing will also be used for non-dilutive working capital and facility enhancements.

In addition to its agreement to acquire InjectEZ, Sharps also announced an associated $400 million 10-year purchase agreement with Nephron Pharmaceuticals, which will advance a manufacturing and research partnership that Sharps announced in November 2022.

The InjectEZ manufacturing facility is located on Nephron’s campus in West Columbus, S.C.

Sharps said it will use debt and preferred stock financing for the acquisition.

Based in New York, N.Y., Sharps is a medical device and pharmaceutical packaging company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.